Rhumbline Advisers Boosts Stake in MorphoSys AG (NASDAQ:MOR)

Rhumbline Advisers grew its position in MorphoSys AG (NASDAQ:MOR) by 17.8% in the second quarter, HoldingsChannel reports. The institutional investor owned 5,187 shares of the company’s stock after acquiring an additional 785 shares during the period. Rhumbline Advisers’ holdings in MorphoSys were worth $94,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of MOR. GAMMA Investing LLC lifted its position in shares of MorphoSys by 47.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,874 shares of the company’s stock worth $52,000 after purchasing an additional 931 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of MorphoSys during the 4th quarter worth approximately $244,000. SAL Trading LLC acquired a new position in shares of MorphoSys in the 1st quarter valued at $486,000. BNP Paribas Financial Markets grew its position in shares of MorphoSys by 130.4% in the 1st quarter. BNP Paribas Financial Markets now owns 32,533 shares of the company’s stock valued at $590,000 after buying an additional 18,413 shares during the last quarter. Finally, Susquehanna International Group Ltd. acquired a new stake in shares of MorphoSys in the 1st quarter valued at about $1,333,000. Hedge funds and other institutional investors own 18.38% of the company’s stock.

MorphoSys Price Performance

Shares of NASDAQ:MOR opened at $18.96 on Tuesday. MorphoSys AG has a 1-year low of $4.18 and a 1-year high of $19.50. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market cap of $2.86 billion, a P/E ratio of -5.45 and a beta of 1.20. The firm has a fifty day moving average price of $18.88 and a 200 day moving average price of $18.46.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.